At last, a clinician’s guidebook to prescription dilemmas. Psychotropic medications prescribed to treat mental disorders have become increasingly commonplace over the past half century, but the decision-making process for doing so continues to lack real clarity. Clinicians and patients alike face new challenges and questions thanks to the increasing availability of these drugs: When is the right time to prescribe something? Can I predict which drug will help this individual? When do I consider changing a medication? How do I assess whether a drug’s side effects make it worthwhile or not? The response to these challenging questions is not to stop medicating altogether. Psychotropic medications are useful clinical tools. But now more than ever we must consider what it means to medicate judiciously. It is time to slow down, pause, maybe even back up a bit, and reconsider how and why various drugs should be prescribed and monitored for success. The goal of this book is to encourage prudent, informed, and appropriate use of psychotropic medications—to encourage use that is respectful and aware of the strengths and limitations of these drugs. By presenting some fundamental principles of pharmacology as they apply to the clinical treatment of patients, and by offering practical, big-picture prescribing recommendations, Psychopharmacology Problem Solving helps to unravel an increasingly complex decision-making process. The first part of the book offers guidelines to keep in mind when working toward making informed choices regarding drug therapy. The second part of the book offers select examples of behavioral problems and psychological disorders—including addiction, obesity, schizophrenia, depression, anxiety, and ADHD—to illustrate how the principles or recommendations presented in Part I actually play out. The book concludes by considering the persistent problems and challenges that we face in our current and future use of psychotropic medications. Taking a hard look at the extraordinary and increasing trust clinicians, patients, and families of patients place in drug therapy for mental illness, this book gives readers an evidence-based anchor to help them make the right decisions.

At last, a clinician’s guidebook to prescription dilemmas. Psychotropic medications prescribed to treat mental disorders have become increasingly commonplace over the past half century, but the decision-making process for doing so continues to lack real clarity. Clinicians and patients alike face new challenges and questions thanks to the increasing availability of these drugs: When is the right time to prescribe something? Can I predict which drug will help this individual? When do I consider changing a medication? How do I assess whether a drug’s side effects make it worthwhile or not? The response to these challenging questions is not to stop medicating altogether. Psychotropic medications are useful clinical tools. But now more than ever we must consider what it means to medicate judiciously. It is time to slow down, pause, maybe even back up a bit, and reconsider how and why various drugs should be prescribed and monitored for success. The goal of this book is to encourage prudent, informed, and appropriate use of psychotropic medications—to encourage use that is respectful and aware of the strengths and limitations of these drugs. By presenting some fundamental principles of pharmacology as they apply to the clinical treatment of patients, and by offering practical, big-picture prescribing recommendations, Psychopharmacology Problem Solving helps to unravel an increasingly complex decision-making process. The first part of the book offers guidelines to keep in mind when working toward making informed choices regarding drug therapy. The second part of the book offers select examples of behavioral problems and psychological disorders—including addiction, obesity, schizophrenia, depression, anxiety, and ADHD—to illustrate how the principles or recommendations presented in Part I actually play out. The book concludes by considering the persistent problems and challenges that we face in our current and future use of psychotropic medications. Taking a hard look at the extraordinary and increasing trust clinicians, patients, and families of patients place in drug therapy for mental illness, this book gives readers an evidence-based anchor to help them make the right decisions.

This book aims to provide comprehensive, up-to-date information on psychotropic drugs and inform clinical decisions for the treatment of mental disorders using a problem-solving approach.In order to accomplish these goals, the book has three central characteristics:More than a textbook, it is meant to serve as a practical tool for professionals working in the mental health field.

This indispensable book provides therapists and counselors with crucial knowledge about psychotropic medications: when and how to make medication referrals, how to answer patients' questions and help them handle problems that arise, and how to combine medication and psychotherapy effectively. Ideal for readers without extensive background in neurobiology, the book clearly explains how medications work in the brain and how they affect an individual's emotions, behavior, and relationships. Strategies for collaborating successfully with patients, their family members, and prescribers are discussed in detail. In this edition, psychopharmacology content has been fully updated.

"The troubling increase in treatment resistance in psychiatry has many culprits: the rise of biomedical psychiatry and corresponding sidelining of psychodynamic and psychosocial factors; the increased emphasis on treating the symptoms rather than the person; and a greater focus on the electronic medical record rather than the patient, all of which point to a breakdown in the person-centered prescriber-patient relationship. Psychodynamic Psychopharmacology illuminates a new path forward. It examines the psychological and interpersonal mechanisms of pharmacological treatment resistance, integrating research on evidence-based prescribing processes with psychodynamic insights and skills to enhance treatment outcomes for patients who are difficult to treat. The first part of the book explores the evidence base that guides how, rather than simply what, to prescribe. It describes precisely what psychodynamic psychopharmacology is and why its emphasis on combining the often-neglected psychosocial aspects of medication with biomedical considerations provides a more optimized approach to addressing treatment resistance. Part II delves into the psychodynamics that contribute to pharmacological treatment resistance, both when patients' ambivalence about their illness, the medication itself, or their prescriber manifests in nonadherence and when medications support a negative identity or are used as replacements for healthy capacities. Readers will gain basic skills for addressing the psychological and interpersonal dynamics that underpin both scenarios and will be better positioned to ameliorate interferences with the healthy use of medications. The final section of the book offers detailed technical recommendations for addressing pharmacological treatment resistance. It tackles issues that include countertransference-driven irrational prescribing; primitive dynamics, such as splitting and projective identification; and the overlap between psychopharmacological treatment resistance and the dynamics of treatment nonadherence and nonresponse in integrated and collaborative medical care settings. By putting the individual patient back at the center of the therapeutic equation, psychodynamic psychopharmacology, as outlined in this book, offers a model that moves beyond compliance and emphasizes instead the alliance between patient and prescriber. In doing so, it empowers patients to become more active contributors in their own recovery"--

A generation of social work students has benefited from Kia Bentley and Joseph Walsh’s practical approach to the social worker’s role in psychopharmacology. New coauthor Shannon Hughes brings even more fresh ideas to the updated Fifth Edition. Important updates include: • updated and expanded drug information and tables including names, typical dosages, potential adverse effects, as well as never-before-included FDA approval information • updated content on psychogenomics as well as added new content on medication use with sexual minorities and gender diverse people • more explicit criticisms of the chemical imbalance theory and the use of the term “anosognosia” • more comprehensive guidelines for talking to children, parents, and teachers about psychiatric medication • expanded content on shared decision-making, including a presentation on what we think “truth-telling” about medication looks like in the 21st century • explicit content on the centrality of avoiding both subtle and overt coercion • new section on medication discontinuation and “deprescribing” and the role of social work in supporting these trends • expanded section on prescription-writing privileges to account for the recognition of physician assistants, nurse practitioners, and pharmacists in those roles • new section on the use of psychedelics in psychiatry • acknowledgement of the potential impact of the COVID-19 pandemic and telemedicine on the future of both social work and psychopharmacological practice • significantly increased attention to the human rights/social justice interface of social work and psychopharmacology